A detailed study of the above results concluded that NMJ-2 and NMJ-3 can inhibit the NOTCH-1 overexpression by activation of SIRT-1 in NAFLD/NASH in comparison with vorinostat. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatohepatitis.